Announced ITF 2 October: Adsure Services, the holding company for TIAA Limited, a specialist business assurance provider operating across the Housing, Healthcare, Government, Education, Charities, and other sectors in the UK, intends to join the Access Segment of the AQSE Growth Market. Admission expected on 30 October.
MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. Admission delayed, expected mid-November.
Argentex Group 75.5p £85.5m (AGFX.L)
The service-led, tech-enabled provider of currency management and payment services to international institutions and corporates announces that Harry Adams, Chief Executive Officer, has left the Company with immediate effect. Jim Ormonde, has been appointed to act as Chief Executive Officer on an interim basis. Mr Ormonde was CEO of Cardsave, one of Europe's independent payments businesses. He was also a director of Retail Merchant Services which was sold successfully to TCV Private Equity.
Cleantech Lithium 36p £35.3m (CTL.L)
An exploration and development company advancing sustainable lithium projects in Chile for the clean energy transition announces that the Company has entered into a strategic partnership (Partnership) with the University of Atacama in Chile. The Partnership aims to secure a sustainable and skilled workforce, develop research initiatives and nurture the next generation of lithium industry professionals in the Atacama region.
Cornish Metals 10p £52.1m (CUSN.L)
A mineral exploration and development company focused on its South Crofty Tin Project (Project) in Cornwall reports that it has opened the Water Treatment Plant (WTP). Following successful wet commissioning of the WTP and the building of a high-density sludge bed within the plant, the Company announce that the discharge of treated water from South Crofty Mine to the Red River will commence from the week of October 30 at a rate of up to 25,000m3/day. Mine dewatering is expected to take 18 months. The treated water meets the Company's permitted standards set by the Environment Agency for discharge into the Red River and will have a positive effect on water quality as a consequence.
Evgen Pharma 1.95p £5.4m (EVG.L)
The clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases and Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Center, announce the formal start of their collaborative project in glioblastoma, supported with a grant awarded by the KWF Dutch Cancer Society. The project formally commenced on 1 October in which EUR1.1m has been awarded by the KWF Dutch Cancer Society. The project will investigate the use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study .
Haydale Graphene Industries 0.425p £7.6m (HAYD.L)
The advanced materials group announces its full year results for the year ended 30 June 2023 (FY23). Revenue of £4.30m (FY22: £2.90m) was up by 48.3% on the prior year, the adjusted operating loss has increased marginally by £0.16m to £3.49m (FY22: £3.33m) and the Company announced a £5.1m fundraise post period. The Company announced that it has signed commercial agreements with industry partners Saint Gobain, Cadent and Petronas and are also working with several other nanomaterial producers. The Board remains confident that the Company will be able to take advantage of the traction.
Hummingbird Resources 8.75p £52.7m (HUM.L)
A multi-asset, gold producing Company, with two core gold projects, the operational Yanfolila Gold Mine in Mali, and the Kouroussa Gold Mine in Guinea announces a trading update. The Group announced adjusted EBITDA of c.US$1.2m, vs a loss of US$8.9m in Q3-2022. The Company held a net debt position of c.US$123.0m, held cash at bank of c.US$15.1m and gold inventory value of c.US$3.4m. Yanfolila produced 18,399 ounces (oz) of gold in Q3-2023, an increase of c.9% and all-in sustaining costs on gold produced totalled US$1,651 per oz in Q3-2023, a decrease of c.24% on Q3 2022 (US$2,161 per oz). Kouroussa produced 1,047 oz of gold. The Company's updated production expectations for H2-2023 are c.10,000 oz.
Ironveld 0.26p £9.3m (IRON.L)
The mining development company confirms that its largest shareholder, Tracarta Limited has subscribed for new Ordinary shares totaling £450k in the Company at a price per share of 0.278p, representing a premium of 23.5 per cent. to the closing mid-price of 0.225p on 25 October 2023. In addition the Company's Broker, has procured orders for a further £550k from existing shareholders on the same terms. Dr John Wardle will assume the role of Executive Chairman of the Company, with Giles Clarke remaining as a Non-Executive Director.
Kibo Energy* 0.053p £2.0m (KIBO.L)
The renewable energy-focused development company announces that further to its RNS announcement of 5 October 2023 on receipt of 31,646,424 shares from Mast Energy Development PLC (MED), in lieu of cash for partial settlement of £469k, the Company has decided to realise a portion of said share payment in cash with net proceeds of £259.8k through the sale of 20,250,000 of said Settlement Shares. As a result of this recent disposal of its MED shares, the Company's beneficial holding in MED now stands at 48.35%. The proceeds will be used for Kibo's on-going working capital requirements, with the balance going towards funding its group companies and to reduce the outstanding balance on the Company's reprofiled bridge loan facility with RiverFort Global Opportunities PCC Ltd.
Kromek Group 4.8p £28.8m (KMK.L)
A developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments announces that it has been awarded a $5.9m contract from the US Department of Homeland Security Countering Weapons of Mass Destruction Office for the research and development of technologies focusing on an agent agnostic bio-detection system. The contract has been awarded under a four-year programme, commencing immediately, and the Group expects to receive $874k during the first year base period.
Poolbeg Pharma* 6.75p £33.8m (POLB.L)
A clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need announces that its Scientific Advisory Board (SAB) has endorsed the influenza drug targets identified in its AI-led drug discovery programme. The SAB was presented with comprehensive data regarding the large number of novel drug targets identified as part of the CytoReason collaboration in June 2023. A consensus was reached on the prioritised list of novel drug targets to bring forward for lab-based validation, which is expected to complete in 2024. The Company continues to discuss the exciting outputs from its AI-led drug discovery programmes with prospective partners.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
